Role of flavonoids in management of various biological targets in Alzheimer's Disease: evidence from preclinical to clinical studies.

Alharbi, KS; Javed Shaikh, MA; Imam, SS; Alshehri, S; Ghoneim, MM; Almalki, WH; Singh, SK; Kumar, D; Kumar, AP; Dua, K; Chellappan, DK; Paudel, KR; Gupta, G

Role of flavonoids in management of various biological targets in Alzheimer's Disease: evidence from preclinical to clinical studies.

Alharbi, KS Javed Shaikh, MA Imam, SS Alshehri, S Ghoneim, MM Almalki, WH Singh, SK Kumar, D Kumar, AP Dua, K

Chellappan, DK Paudel, KR Gupta, G

Permalink

Publisher:: Bentham Science Publishers Ltd.
Publication Type:: Journal Article
Citation:: Curr Med Chem, 2022, 30
Issue Date:: 2022-11-22

Closed Access

	Filename	Description	Size
	9685609500005671.pdf		1.39 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Alharbi, KS
dc.contributor.author	Javed Shaikh, MA
dc.contributor.author	Imam, SS
dc.contributor.author	Alshehri, S
dc.contributor.author	Ghoneim, MM
dc.contributor.author	Almalki, WH
dc.contributor.author	Singh, SK
dc.contributor.author	Kumar, D
dc.contributor.author	Kumar, AP
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Chellappan, DK
dc.contributor.author	Paudel, KR
dc.contributor.author	Gupta, G
dc.date.accessioned	2023-01-18T04:40:43Z
dc.date.available	2022-09-30
dc.date.available	2023-01-18T04:40:43Z
dc.date.issued	2022-11-22
dc.identifier.citation	Curr Med Chem, 2022, 30
dc.identifier.issn	0929-8673
dc.identifier.issn	1875-533X
dc.identifier.uri	http://hdl.handle.net/10453/165114
dc.description.abstract	More than 10 million people worldwide have Alzheimer's disease (AD), a degenerative neurological illness and the most prevalent form of dementia. AD's progression in memory loss, cognitive deterioration, and behavioral changes are all symptoms. Amyloid-beta 42 (Aβ42), the hyperphosphorylated forms of microtubule-associated tau protein, and other cellular and systemic alterations are all factors that contribute to cognitive decline in AD. Rather than delivering a possible cure, present therapy strategies focus on reducing disease symptoms. It has long been suggested that various naturally occurring small molecules (plant extract products and microbiological isolates, for example) could be beneficial in preventing or treating disease. Small compounds, such as flavonoids, have attracted much interest recently due to their potential to alleviate cellular stress. Flavonoids have been proven helpful in various ways, including antioxidants, anti-inflammatory agents, and anti-apoptotic agents, but their mechanism remains unknown. The flavonoid therapy of Alzheimer's disease focuses on this review, which includes a comprehensive literature analysis.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Bentham Science Publishers Ltd.
dc.relation.ispartof	Curr Med Chem
dc.relation.isbasedon	10.2174/0929867330666221122115212
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0304 Medicinal and Biomolecular Chemistry, 0601 Biochemistry and Cell Biology, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.title	Role of flavonoids in management of various biological targets in Alzheimer's Disease: evidence from preclinical to clinical studies.
dc.type	Journal Article
utslib.citation.volume	30
utslib.location.activity	United Arab Emirates
utslib.for	0304 Medicinal and Biomolecular Chemistry
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
pubs.organisational-group	/University of Technology Sydney/Strength - CFI - Centre for Inflammation
utslib.copyright.status	closed_access	*
dc.date.updated	2023-01-18T04:40:42Z
pubs.publication-status	Published online
pubs.volume	30

Abstract:

More than 10 million people worldwide have Alzheimer's disease (AD), a degenerative neurological illness and the most prevalent form of dementia. AD's progression in memory loss, cognitive deterioration, and behavioral changes are all symptoms. Amyloid-beta 42 (Aβ42), the hyperphosphorylated forms of microtubule-associated tau protein, and other cellular and systemic alterations are all factors that contribute to cognitive decline in AD. Rather than delivering a possible cure, present therapy strategies focus on reducing disease symptoms. It has long been suggested that various naturally occurring small molecules (plant extract products and microbiological isolates, for example) could be beneficial in preventing or treating disease. Small compounds, such as flavonoids, have attracted much interest recently due to their potential to alleviate cellular stress. Flavonoids have been proven helpful in various ways, including antioxidants, anti-inflammatory agents, and anti-apoptotic agents, but their mechanism remains unknown. The flavonoid therapy of Alzheimer's disease focuses on this review, which includes a comprehensive literature analysis.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/165114